Acadia Pharmaceuticals (ACAD) Assets (2010 - 2026)
Acadia Pharmaceuticals' quarterly Assets came in at $1.6 billion in Q1 2026, up 41.76% year-on-year from $1.1 billion in Q1 2025, and up 2.62% quarter-over-quarter from $1.6 billion in Q4 2025.
Acadia Pharmaceuticals has reported Assets for 17 years, with the latest figure at $1.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 41.76% year-over-year to $1.6 billion; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (up 41.76% YoY), and the FY2025 full-year result was $1.6 billion, up 31.69% from the prior year.
- Assets for Q1 2026 stood at $1.6 billion, up from $1.6 billion in the prior quarter.
- The five-year high for Assets was $1.6 billion in Q1 2026, with the low at $587.8 million in Q4 2022.
- Average Assets over 5 years is $935.2 million, with a median of $855.1 million recorded in 2024.
- Year-over-year, Assets retreated 17.34% in 2022 and soared 58.59% in 2024.
- Tracing ACAD's Assets over 5 years: stood at $587.8 million in 2022, then increased by 27.41% to $749.0 million in 2023, then soared by 58.59% to $1.2 billion in 2024, then surged by 31.69% to $1.6 billion in 2025, then rose by 2.62% to $1.6 billion in 2026.
- The last three Assets figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | 1.61 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Bn |
| Dec 31, 2025 | 1.56 Bn |
| Sep 30, 2025 | 1.33 Bn |
| Jun 30, 2025 | 1.23 Bn |
| Mar 31, 2025 | 1.13 Bn |
| Dec 31, 2024 | 1.19 Bn |
| Sep 30, 2024 | 976.87 Mn |
| Jun 30, 2024 | 914.10 Mn |
| Mar 31, 2024 | 855.10 Mn |
| Dec 31, 2023 | 748.96 Mn |
| Sep 30, 2023 | 632.54 Mn |
| Jun 30, 2023 | 642.77 Mn |
| Mar 31, 2023 | 655.31 Mn |
| Dec 31, 2022 | 587.81 Mn |
| Sep 30, 2022 | 602.49 Mn |
| Jun 30, 2022 | 612.77 Mn |
| Mar 31, 2022 | 624.25 Mn |
| Dec 31, 2021 | 700.12 Mn |
| Sep 30, 2021 | 717.67 Mn |
| Jun 30, 2021 | 724.43 Mn |
| Mar 31, 2021 | 755.17 Mn |
| Dec 31, 2020 | 782.62 Mn |
| Sep 30, 2020 | 795.66 Mn |
| Jun 30, 2020 | 759.65 Mn |
| Mar 31, 2020 | 747.45 Mn |
| Dec 31, 2019 | 783.18 Mn |
| Sep 30, 2019 | 765.59 Mn |
| Jun 30, 2019 | 460.88 Mn |
| Mar 31, 2019 | 501.11 Mn |
| Dec 31, 2018 | 540.20 Mn |
| Sep 30, 2018 | 266.46 Mn |
| Jun 30, 2018 | 314.96 Mn |
| Mar 31, 2018 | 351.04 Mn |
| Dec 31, 2017 | 384.51 Mn |
| Sep 30, 2017 | 413.71 Mn |
| Jun 30, 2017 | 456.32 Mn |
| Mar 31, 2017 | 503.01 Mn |
| Dec 31, 2016 | 561.15 Mn |
| Sep 30, 2016 | 617.38 Mn |
| Jun 30, 2016 | 438.03 Mn |
| Mar 31, 2016 | 466.59 Mn |
| Dec 31, 2015 | 221.90 Mn |
| Sep 30, 2015 | 245.32 Mn |
| Jun 30, 2015 | 275.54 Mn |
| Mar 31, 2015 | 301.96 Mn |
| Dec 31, 2014 | 325.46 Mn |
| Sep 30, 2014 | 341.76 Mn |
| Jun 30, 2014 | 359.47 Mn |
| Mar 31, 2014 | 373.51 Mn |
| Dec 31, 2013 | 189.12 Mn |
| Sep 30, 2013 | 199.29 Mn |
| Jun 30, 2013 | 206.91 Mn |
| Mar 31, 2013 | 103.02 Mn |
| Dec 31, 2012 | 108.59 Mn |
| Sep 30, 2012 | 23.75 Mn |
| Jun 30, 2012 | 21.87 Mn |
| Mar 31, 2012 | 26.52 Mn |
| Dec 31, 2011 | 32.11 Mn |
| Sep 30, 2011 | 37.02 Mn |
| Jun 30, 2011 | 41.31 Mn |
| Dec 31, 2010 | 38.39 Mn |